טימנטין 3.2 ג' 이스라엘 - 히브리어 - Ministry of Health

טימנטין 3.2 ג'

glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.

טימנטין 3.2 ג' 이스라엘 - 히브리어 - Ministry of Health

טימנטין 3.2 ג'

glaxo smith kline (israel) ltd - clavulanic acid as potassium 200 mg/vial; ticarcillin as disodium 3 g/vial - powder for solution for infusion - combinations of penicillins - timentin is an injectable antibiotic agent with a broad spectrum of bactericidal activity against a wide range of gram-positive and gram-negative, aerobic and anaerobic bacteria. the presence of clavulanate in the formulation extends the spectrum of activity of ticarcillin to include many beta-lactamase producing bacteria normally resistant to ticarcillin and other beta-lactam antibiotics. timentin is indicated for the treatment of infections in which susceptible organisms have been detected or are suspected. typical indications include: severe infections in hospitalised patients and proven or suspected infections in patients with impaired or suppressed host defences including: septicaemia, bacteraemia, peritonitis, intra-abdominal sepsis, post-surgical infections, bone and joint infections, skin and soft tissue infections, respiratory tract infections, serious or complicated renal infections (e.g. pyelonephritis), ear, nose and throat infections.

לוסנטיס 이스라엘 - 히브리어 - Ministry of Health

לוסנטיס

novartis israel ltd - ranibizumab - תמיסה להזרקה - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd).treatment of adult patients with visual impairment due to diabetic macular oedema (dme) .the treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (rvo).the treatment of visual impaiment due to choroidal neovacularization (cnv) secondary to pathologic myopia (pm).

אפידיולקס 이스라엘 - 히브리어 - Ministry of Health

אפידיולקס

neopharm ltd, israel - cannabidiol - תמיסה - cannabidiol 100 mg / 1 ml - cannabidiol

ביאוביו 120מגמל 이스라엘 - 히브리어 - Ministry of Health

ביאוביו 120מגמל

novartis israel ltd - brolucizumab - תמיסה להזרקה - brolucizumab 120 mg / 1 ml - brolucizumab

סאליקרן 이스라엘 - 히브리어 - Ministry of Health

סאליקרן

rekah pharmaceutical industry ltd, israel - salicylic acid - משחה - salicylic acid 3 % - salicylic acid - salicylic acid - topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including dandruff, keratosis palmaris and plantaris, psoriasis - keratin of scalp, hands, legs and elbows.